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Abstract
Shrinking lung syndrome (SLS) is a rare and less known complication mainly associated with systemic lupus erythematosus (SLE). In
this study, we analyze the clinical features, investigation findings, approaches to management, and outcome in a case series of 9
adult patients with SLE and SLS diagnosed during a 35-year period in 3 referral tertiary care hospitals in Spain. Additionally, we
reviewed 80 additional cases previously reported (PubMed 1965–2015). These 80 cases, together with our 9 patients, form the basis
of the present analysis.
The overall SLS prevalence in our SLE population was 1.1% (9/829). SLS may complicate SLE at any time over its course, and it
usually occurs in patients without previous or concomitant major organ involvement. More than half of the patients had inactive lupus
according to SELENA-systemic lupus erythematosus disease activity index (SLEDAI) scores. Typically, it presents with progressive
exertional dyspnea of variable severity, accompanied by pleuritic chest pain in 76% of the cases.
An important diagnostic delay is common. The diagnostic tools that showed better yield for SLS detection are the imaging
techniques (chest x-ray and high-resolution computed tomography) along with pulmonary and diaphragmatic function tests.
Evaluation of diaphragm dome motion by M-mode ultrasonography and phrenic nerve conduction studies are less useful.
There are no standardized guidelines for the treatment of SLS in SLE. The majority of patients were treated with medium or high
doses of glucocorticoids. Several immunosuppressive agents have been used in conjunction with steroids either if the patient fails to
improve or since the beginning of the treatment. Theophylline and beta-agonists, alone or in combination with glucocorticoids, have
been suggested with the intent to increase diaphragmatic strength.
The overall long-term prognosis was good. The great majority of patients had significant clinical improvement and stabilization, or
mild to moderate improvement on pulmonary function tests. The mortality rate was very low.
Abbreviations: CTD = connective tissue diseases, DLCO = carbon monoxide gas transfer capacity, FVC = forced vital capacity,
HRCT = high-resolution computed tomography, KCO = carbon monoxide transfer coefficient, MEP =maximal expiratory pressure,
MIP = maximal inspiratory pressure, MRI = magnetic resonance imaging, PFT = pulmonary function test, RTX = rituximab, SD =
standard deviation, SLE = systemic lupus erythematosus, SLS = shrinking lung syndrome.
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Shrinking lung syndrome (SLS) is a rare and less known
complication mainly associated with systemic lupus erythema-
tosus (SLE), although it has also been reported in patients with
other connective tissue diseases (CTDs), including primary
Sjögren syndrome, scleroderma, rheumatoid arthritis, and
undifferentiated connective tissue disorder.[1–4] It is characterized
by progressive dyspnea, usually accompanied by pleuritic chest
pain, diaphragmatic elevation, lung volume reduction with no
parenchymal abnormalities, and a restrictive ventilatory defect in
pulmonary function tests (PFTs).
Many aspects of the disorder remain to be elucidated: its exact
prevalence is unknown, the underlying pathophysiology is
unclear, and the best treatment and prognosis remain controver-
sial.
In the present study, we analyze the clinical features,
investigation findings, approaches to management, and outcomes
in a series of adult patients with SLS associated with SLE.We also
reviewed the available literature to summarize the experience
with this complication.
Borrell et al. Medicine (2016) 95:33 Medicine2. Patient and methods
2.1. Patient selection
The sample included all adult patients (n=9) with SLS and SLE
(all of whom met the American College of Rheumatology
classification criteria for SLE),[5] who were routinely treated from
January 1980 toMay 2015 at the rheumatology departments of 3
referral tertiary care hospitals in Spain and followed for at least 6
months after SLS diagnosis. A retrospective analysis of
prospectively collected data was performed.
Patients were considered to have an SLS if the following
conditions were present: a compatible clinical picture (progres-
sive exertional dyspnea of variable severity with or without
pleuritic chest pain); lung volume reduction and restrictive
ventilatory defect in PFT; and no evidence of parenchymal lung
disease or vascular pathology on imaging (chest x-ray and
thoracic high-resolution computed tomography [HRCT]) find-
ings. The inpatient and outpatient charts of the patients were
comprehensively reviewed by the study investigators to obtain
clinical, laboratory, and disease course data.
The medical records of the patients with SLS and SLE were
transcribed onto a specific form that included the following
information: baseline demographic characteristics; disease dura-
tion; other previous and concomitant clinical features of lupus;
SELENA-systemic lupus erythematosus disease activity index
(SLEDAI) at SLS diagnosis; presenting features of SLS; diagnostic
studies; treatment; and long-term outcome.
In accordance with the guidelines of our institutional ethics
committee, formal approval for this study was not required. The
local ethics committee agreed that the findings in this report were
based on normal clinical practice and were therefore suitable for
dissemination. Informed consent was not obtained from the
patients, but their clinical records and information were67 potenally relevant citaons 
idenfied in PubMed
59 arcles retrieved for 
detailed evaluaon
35 arcles included in 
the systemac review
9 arcles from previous 
references
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anonymized before analysis. This study was conducted in
accordance with the principles of the Declaration of Helsinki
and the International Conference for Harmonization.2.2. Literature search strategy and selection criteria
Searches were conducted in the PubMed database (i.e., including
MEDLINE, National Library of Medicine, and PubMed Central)
for the period between January 1965 and November 2015, using
strategies recommended by the Cochrane handbook. The
keyword used was “shrinking lung syndrome.” Only English,
French, Portuguese, and Spanish reports were considered. To
standardize the information, we excluded: patients aged less than
18 years, pregnant women, and patients with overlap syndromes
or with SLS associated with other CTDs different from SLE.
Reference lists of original studies were manually searched, and
relevant articles were extracted. The references of the studies
obtained were also examined to identify additional reports. The
manuscripts of all potentially relevant studies identified during
the search of abstracts were then retrieved and reviewed.
The MEDLINE search resulted in 67 articles (Fig. 1). Of them,
8 were excluded because they were not related with CTD.[6–13]
The remaining 59 articles were evaluated, together with 9
additional reports identified from the revision of the references.
After evaluation of the full text, 33of these articleswere excluded:
15were a review or contained irrelevant data[14–28]; 7 corresponded
to pregnant or pediatric cases[29–35]; and 6 were overlap
syndromes[36,37] or cases of SLS associated with other CTDs
different from SLE.[1–4] Finally, we also excluded the cases reported
by Allen et al[38] (11 cases), Gibson et al[39] (7 cases), Gheita et al[40]
(8 cases), Elkayam et al[41] (2 cases), and 1 case published by Rubin
and Urowitz[42] because their clinical characteristics were not
sufficiently detailed to be individually analyzed.8 citaons excluded as
not related with CTD
33 arcles excluded
- 6 pediatrics
- 6 other CTD or overlaps
- 1 pregnancy
- 5 clinical characteriscs of the 
paents were not sufficiently 
detailed to be analyzed 
individually
- 15 review/non including cases 
arcles
ch: process selection.
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identifying 80 well-documented cases of adult SLE patients with
SLS.[43–77]2.3. Statistical analysis
Qualitative variables were described by frequencies and
percentages, and quantitative variables by mean or median±
standard deviation (SD) and range.3. Results
The main clinical characteristics and outcome of the 9 patients
with SLS and SLE diagnosed in our institutions are summarized
in Table 1. The overall SLS prevalence in our lupus population
during a 35-year period was 1.1% (9/829).
The main clinical characteristics and outcome of the 80
patients obtained from the literature are summarized in Table 2.
Because it is a review of the literature, not all analyzed variables
were recorded in all published cases. Thus, the results
(percentages) in each variable were calculated considering only
the number of patients in which the data have been documented.
The global analysis of the 89 patients available for review
provided the following information.3.1. Demographic data
Of the 89 patients, 84 were women (94%) and 5 (6%) were men,
with a female-to-male ratio of 17:1, and ages ranging from 19 to
69 years (mean 36±12 years). The median duration of
SLE before the diagnosis of SLS was 4±6.5 years (range
1–420 months). In 9% of the cases (6/69), SLS was the presenting
feature of SLE.
3.2. Other previous and concomitant clinical
manifestations of SLE
The majority of patients did not have previous or concomitant
major organ involvement other than SLS. The most common
clinical features of lupus were arthritis and dermatologic
involvement and, less commonly, serositis (mainly pleuritis).
Nephritis was documented in 31% (17/54) of the patients.
Regarding their autoantibody profile, 81% (39/48) of patients
tested positive for anti-dsDNA antibodies, whereas anti-SSA/Ro
antibodies were positive in only 35% (11/31) of the patients in
whom this information was available.
Active disease (defined as a SELENA-SLEDAI score ≥6) at SLS
diagnosis was present in 44% (18/41) of the patients. Only 15%
(6/41) of them had a severe lupus flare (defined as a SELENA-
SLEDAI score ≥12).
3.3. Presenting features of SLS
Almost all patients (88/89) presented exertional dyspnea of
variable severity that progressed in some cases, over different
periods, to breathlessness at rest. Concomitant pleuritic chest
pain was common, being reported in 76% (60/79) of the patients.
Orthopnea may also occur because of diaphragmatic weakness.
Fever or dry cough was more rarely seen (19% [15/79] and 8%
[6/79], respectively). In 73% (56/77) of patients, the syndrome
was bilateral.
The most frequent findings on clinical examination were
tachypnea associated with limited chest wall examination,
frequently with use of the accessory muscles of respiration.3
Lung auscultation often is normal, although bibasal crepitations
may be heard in the presence of basal atelectasis.
An important diagnostic delay was common. The mean
duration of symptoms before the diagnosis was 11±20 months.
In 48% (15/31) of the patients, the average duration of symptoms
before the SLS diagnosis was longer than a year.3.4. Imaging techniques
In the majority of patients, both chest x-ray and thoracic HRCT
was employed to establish the diagnosis. The most frequent chest
x-ray finding was elevated unilateral or bilateral hemidiaph-
ragms, with reduced lung volumes being observed in 69% of
patients (49/71). In some, it was associated with basal linear
atelectasis (41% [29/71]) and/or mild pleural effusions or pleural
thickening (23% [16/71]). The chest radiograph was described as
normal in only 3% of the patients (2/62).
High-resolution computed tomography was more sensitive
than x-ray in detecting mild pleural effusions/thickening or
atelectasis (47% [28/59] and 37% [22/59] of the cases,
respectively), but its main utility was in ruling out the presence
of parenchymal lung disease or vascular pathology.
The usefulness of the evaluation of diaphragm domemotion by
M-mode ultrasonography was lesser, establishing the diagnosis
only in 46% (6/13) of the patients. The paralyzed side shows no
active caudal movement of the diaphragm, with inspiration and
abnormal paradoxical movement (i.e., cranial movement on
inspiration), particularly with the sniff test.
Dynamic contrast-enhanced lung magnetic resonance imaging
(MRI) was employed only in 1 case.3.5. Pulmonary and diaphragmatic function tests
Results of PFT were abnormal in all patients described, showing
characteristically a restrictive defect with reduced lung volumes
and carbon monoxide gas transfer capacity (DLCO).
Forced vital capacity (FVC) ranged from 21% to 80% of
predicted capacity, with an overall mean value of 48±16%. Both
the total lung capacity (TLC) and the DLCOwere reduced (mean
values of 57±17% and 48±16% of predicted, respectively),
whereas the carbon monoxide transfer coefficient (KCO) (i.e.,
corrected for alveolar volume) was generally normal.
Measures of diaphragmatic muscle strength were also of great
utility to confirm the suspicion of SLS. The great majority of these
patients (89% [32/36]) had a decrease in maximal inspiratory
pressure (MIP) and maximal expiratory pressure (MEP),
indicating a global respiratory muscle weakness. The overall
mean values of MIP and MEP were reduced: 43±17% and
42±20% of the predicted values, respectively.
3.6. Electromyography
Phrenic nerve conduction studies were performed in 17 patients,
and showed normal results in 13 (76%), and also decreased or
absent response to stimulation in the remaining 4.
3.7. Treatment
The great majority of patients (95%) [63/66] were treated with
medium or high doses of glucocorticoids (53% [35/66] were
treated with initial doses >30mg/daily of prednisone or
equivalent). Two patients received intravenous methylpredniso-
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Table 2
Clinical characteristics and outcome of 80 reported adult SLE patients with SLS.
Variable
Number (%) of patients in
whom these data were recorded
Results considering only the number of
patients in whom these data were recorded
Age (mean±SD, yrs) 80/80 (100%) 36±13
Sex (female/male) 80/80 (100%) 75 (94%) / 5 (6%)
Disease duration (median±SD, mos) 60/80 (75%) 48±77
Duration of symptoms before SLS diagnosis/diagnostic delay (median±SD, mos) 31/80 (39%) 11±20











FVC 67/80 (84%) 47±15
FEV1 30/80 (38%) 47±17
FVC/FEV1 30/80 (38%) 83±10
TLC 44/80 (55%) 54±14
DLCO 32/80 (40%) 49±14
Restrictive pattern 79/80 (99%) 79/79 (100%)
Chest x-ray findings 62/80 (78%)
Diaphragm elevation/reduced lung volumes 40/62 (65%)
Basal atelectasis 25/62 (40%)
Thickening or pleural effusion 12/62 (19%)
Normal 2/62 (3%)
M-mode ultrasonography of the diaphragm 13/80 (16%)
Normal 7/13 (54%)
Decrease or absence of movement 6/13 (46%)
High-resolution computed tomography findings 50/80 (61%)
Basal atelectasis 14/50 (28%)
Thickening or minimal pleural effusion 23/50 (46%)
Interstitial lung disease 0/50 (0%)
Diaphragmatic function tests (mean±SD, %)
Maximum inspiratory pressure (MIP) 27/80 (34%) 43±17
Maximum expiratory pressure (MEP) 22/80 (27%) 42±20
Phrenic nerve stimulation 17/80 (21%)
Normal 13/17 (76%)
Decrease or absence of response 4/17 (24%)
Positive anti-DNAn antibodies 39/80 (49%) 30/39 (77%)
Positive anti-Ro/anti-La antibodies 25/80 (36%) 10/25 (40%)
SELENA-SLEDAI 35/80 (44)
Mild/inactive 21/35 (60%)
Active (SLEDAI ≥6) 14/35 (40%)
Unilateral/bilateral SLS involvement 68/80 (85) 17/68 (25%) / 51/68 (75%)
Clinical manifestations 70/80 (88%)
Progressive exertional dyspnea 69/70 (99%)
Chest pain 52/70 (74%)
Fever 12/70 (17%)










Follow-up time (median±SD, mos) 27/80 (34%) 24±30
Long-term outcome 45/80 (58%)
Cured without sequelae 9/45 (20%)
Chronic restrictive defect on PFT 36/45 (80%)
Development of radiologic ILD 0/45 (0%)
Exitus 1/45 (2%)
The results are presented as the means or medians± standard deviation or the number of cases with percentages.
APS= antiphospholipid syndrome, DLCO=diffusing capacity of the lungs for carbon monoxide, FEV1= forced expiratory volume in 1 second, FVC= forced vital capacity, ILD= interstitial lung disease, PFT=
pulmonary function test, TLC= total lung capacity, SLEDAI = systemic lupus erythematosus disease activity index, SD= standard deviation.
Borrell et al. Medicine (2016) 95:33 www.md-journal.com
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Borrell et al. Medicine (2016) 95:33 MedicineIn more than half of the patients, immunosuppressive agents
were used in conjunction with steroids since the beginning of the
treatment, or when the patient failed to improve. The most
frequently used were azathioprine (20 cases) and cyclophospha-
mide (13 cases). There is also limited experience with
mycophenolate mofetil and methotrexate. Rituximab (RTX) is
increasingly being used in severe or refractory cases of SLS (9
patients), with effectiveness and good safety profile.[22,52,54,59]
Theophylline (15% [10/66] of cases) and beta-agonists (20%
[13/66]), alone or in combinationwith glucocorticoids, have been
also employed with the intent to increase diaphragmatic strength.
Information about the duration of applied treatment,
particularly with respect to glucocorticoid regimen and tapering,
was not included in the considered articles.3.8. Outcome
Information about follow-up was available in only 62% (55/89)
of patients. The median of follow-up period was 35±29 months
(range from 6 months to 9 years).
Of the 55 patients, 18% (10/55) cured without functional
sequelae; the other patients had significant clinical improvement
with stabilization or mild to moderate improvement on
PFT after treatment. Despite the persistence of a chronic
restrictive defect in these patients, none required chronic home
oxygen therapy.
Only 1 patient died because of pneumonia,[42] but she also had
concomitant active lupus nephritis and poor medication adher-
ence. In addition, 1 patient finally developed interstitial lung
disease (nonspecific interstitial pneumonitis) 4 years after SLS
onset.4. Discussion
Shrinking lung syndrome is a rare complication of SLE. Our data
confirm its low prevalence, estimated between 0.5% and 1.1% in
the general lupus population.[24,50] It may complicate SLE at any
time over its course, ranging from as early as 1 month to 35 years
after disease onset. Although it is much more frequent in
advanced stages of the disease, rarely, SLS may be the presenting
manifestation of SLE.[43,48,57,66,69,76] This complication is more
common in SLE patients of female sex, with a female-to-male
ratio of 17:1.
The major symptom of SLS is progressive exertional dyspnea
of variable severity, accompanied by pleuritic chest pain in three-
quarters of patients. This complication usually occurs in patients
without previous or concomitant major organ involvement other
than SLS, and, in more than half of the patients, in inactive stages
of the disease, according to SELENA-SLEDAI scores.[43–77]
An important diagnostic delay is observed in the clinical
practice, indicating that SLS is still an under-recognized
pulmonary complication of SLE. Despite its rarity, SLS should
be considered in the differential diagnosis of lupus patients with
dyspnea and/or pleuritic chest pain. In many ways, it represents a
diagnosis of exclusion. In this sense, the recommended first-line
procedures for diagnosis should include chest x-ray and thoracic
HRCT, along with pulmonary and diaphragmatic function tests.
The most distinctive findings of this entity were elevated
unilateral or bilateral hemidiaphragms with reduced lung
volumes, a restrictive ventilatory defect in PFT with reduced
TLC and DLCO in absence of parenchymal lung disease or
vascular pathology on imaging techniques, and reduced MIP and
MEP.[17,43–77]6
The evaluation of diaphragm dome motion by M-mode
ultrasonography or dynamic contrast-enhanced lung MRI might
be a useful second-line tool to reinforce clinical suspicion in cases
of diagnostic difficulty. The accumulated experience with
dynamic contrast-enhanced lung MRI is still scarce. In the only
case reported to date,[74] it detected the presence of subjacent
pleural inflammation as an underlying cause of this condition,
without evidence of myositic changes involving the diaphragm,
and dynamic MRI sequences on forced voluntary ventilation
confirmed physiologic movements of both diaphragms and all
auxiliary respiratory muscles. According to the preliminary data,
dynamic MRI might emerge as a useful second-line tool in the
diagnosis of SLS. On the contrary, the diagnostic usefulness of the
electromyography seems poor.[16,17,45,66]
There are no standardized guidelines for the treatment of SLS
in SLE. According to the available experience, the majority of
patients should be initially treated with medium or high doses of
glucocorticoids.[43–77] An immunosuppressive agent in conjunc-
tion with steroids should be used if the patient fails to improve,
and it is advisable from the beginning of the treatment in patients
with severe clinical and functional decline, but there are no
randomized controlled trials to provide data concerning their
efficacy. The most widely used drugs were azathioprine and
cyclophosphamide, with variable success.[43–77] Further, RTX is
used in severe or refractory SLS (9 patients), with effectiveness
and good safety profile in all cases.[22,52,54,59] Based on this
preliminary experience, RTX might emerge as the first-choice
immunosuppressant, particularly in patients with severe or
refractory disease, although larger-cohort studies must be
performed in this field to confirm the efficacy of RTX in SLS.
Theophylline and beta-agonists, alone or in combination with
glucocorticoids, have also been suggested with the intent to
increase diaphragmatic strength, but evidence of beneficial effects
is lacking. Information about the duration of applied treatment,
particularly with respect to glucocorticoid regimen and tapering,
was not specified in the revised articles. In addition, the dose and
duration of corticosteroids required for controlling SLS have
never been tested in a randomized trial design. So it must be
individualized based on the clinical response and evolution of
pulmonary and diaphragmatic function tests, but taking also into
account the recent recommendations for a more rational
prescription of glucocorticoids.[78,79]
The overall response to treatment is positive. The great
majority of patients had significant clinical improvement and
stabilization, or mild to moderate improvement on PFT.[17,43–77]
Despite the persistence of a chronic restrictive defect in most of
these patients, none required chronic home oxygen therapy, and
death because of respiratory failure or associated complications
was extremely rare, indicating a low-grade defect.
In interpreting the results of our study, one needs to consider its
potential limitations derived from its observational nature, the
small sample size, and the lack of multiple center’s data. In
addition, we cannot ignore the pitfalls inherent in any systematic
review including the relatively small number of identified
patients, the retrospective design, and incomplete follow-up data
in some cases.
The precise pathogenic mechanism underlying the SLS remains
controversial. Because pathologic data are unavailable, theories
of its etiology are speculative. In the past, it has been attributed
successively to a surfactant deficiency,[15,43] isolated diaphrag-
matic myopathy,[34,39,44,53,65,67] phrenic nerve dysfunction,[45,66]
chest wall dysfunction,[19,71] and pleural adhesions,[31,39] but
none of these hypotheses has been unequivocally confirmed.
Borrell et al. Medicine (2016) 95:33 www.md-journal.comTo date, data support the hypothesis that SLS may be an
unusual complication of pleuritis, whereby inhibited respiratory
muscle engagement limits inflation and thereby leads to
progressive loss of lung compliance.[16,48,51] Pleuritic chest pain
is a prominent feature of patients with SLS. Our literature search
revealed that 76% of SLS patients had active pleuritic chest pain
at or shortly before clinical manifestation of the syndrome. The
most likely cause of pain is inflammation of the pleural sheets,
involving the diaphragmatic pleura or a pleural region near the
diaphragm. The notion that pleurisy may be the underlying cause
of the diaphragmatic dysfunction is further supported by the
evidence of subjacent pleural inflammation, mild pleural
effusions, or pleural thickening found in the imaging (chest x-
ray, thoracic HRCT, and dynamic contrast-enhanced lung MRI)
of about half of the SLS patients.
The mechanism by which pleural inflammation and pain may
lead to diaphragm dysfunction is probably through reflex
inhibition of diaphragmatic activation.[16,48] Respiratory muscle
function is regulated not only by volition but also through
neuronal reflex arcs. These include the intercostal–phrenic and
pleural–phrenic reflexes, which are activated by stimulation of
intercostal and pleural afferents, respectively, leading to phrenic
nerve inhibition.[80–86] These reflexes have been documented in
humans and may be responsible for decreased inspiratory
capacity in patients after surgery.[87] The pleural–phrenic reflex
can be activated by exposure of the pleura to inflammatory
cytokines.[86] Therefore, it is likely that inflammation of the
parietal pleura may lead to stimulation of unmyelinated or thin
myelinated fibers belonging to the internal intercostal nerves that
normally innervate the costal and the peripheral part of the
diaphragmatic pleura.[48] Pain that typically accompanies pleural
inflammation has profound effects on pulmonary function. The
localized guarding of the muscles in the area of pain, and also the
generalized muscle rigidity, in association with a submaximal
voluntary effort, lead to adoption of a swallow and rapid
breathing pattern, which results in decreased functional residual
capacity (FVC), forced expiratory volume in 1 second, and
TLC.[88]
Therefore, it is hypothesized that pleural inflammation and
pain trigger inhibition of deep inspiration by neural reflexes,
resulting in chronic lung hypoinflation and decreased lung
compliance.[16,48] In this sense, a comparable decrease in lung
compliance has been observed in patients who are chronically
restricted to lower lung volumes, for example, patients with
spinal cord injury or muscular dystrophy.[89–92] The basis of the
impairment of lung compliance is uncertain, although both a
tissue remodeling with changes in the elasticity of the lung tissue
and alterations in surfactant have been implicated as the
underlying pathophysiology.[16,93] Impaired compliance worsens
hypoinflation, initiating a positive feedback loop that helps to
explain the gradual progression of SLS. Because this defect is
primarily functional, the patient’s ventilatory drive would be
expected to limit further respiratory deterioration, thus account-
ing for the low mortality of SLS despite its alarming clinical
presentation. However, that nearly 25% of the reported SLS
cases are not accompanied by pleuritic chest pain raises suspicion
that the pathophysiology of SLS in this subgroup of patients may
be related to another immunological cause that is responsive to
anti-inflammatory and immunosuppressive agents.
In conclusion, SLS represents a rare complication of SLE.
Although uncommon, it is important to be aware of its presenting
features and prognosis because if it is not treated promptly and
aggressively, it can lead to chronic restrictive ventilatory7
dysfunction. Further multicenter controlled studies are required
to define the best diagnostic and treatment options for this
complication.References
[1] Ahmed S, Herrick A, O’Driscoll BR. Shrinking lung syndrome in patients
without systemic lupus erythematosus. Arthritis Rheum 2001;44:243–5.
[2] Blanco Pérez JJ, Pérez González A, Guerra Vales JL, et al. Shrinking lung
in primary Sjögren’s syndrome successfully treated with rituximab. Arch
Bronconeumol 2015;51:475–6.
[3] Tavoni A, Vitali C, Cirigliano G, et al. Shrinking lung in primary
Sjögren’s syndrome. Arthritis Rheum 1999;42:2249–55.
[4] Scirè CA, Caporali R, Zanierato M, et al. Shrinking lung syndrome in
systemic sclerosis. Arthritis Rheum 2003;48:2999–3000.
[5] Hochberg MC. for the Diagnostic, Therapeutic Criteria Committee of
the American College of RheumatologyUpdating the American College
of Rheumatology revised criteria for the classification of systemic lupus
erythematosus. Arthritis Rheum 1997;40:1725.
[6] Zhou ZY, Xu L, Li HG, et al. Chemotherapy in conjunction with
traditional Chinese medicine for survival of elderly patients with
advanced non-small-cell lung cancer: protocol for a randomized double-
blind controlled trial. J Integr Med 2014;12:175–81.
[7] Starczewska MH, Wawrzynska L, Opoka L, et al. Acute lupus
pneumonitis: case report and literature review. Pneumonol Alergol Pol
2013;81:460–7.
[8] Piccolo-Daher S, Magalhães E. Anesthesia in patient with shrinking lung
syndrome: case report. Rev Bras Anestesiol 2012;62:274–80.
[9] Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib
of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma
protuberans. Int J Cancer 2002;100:623–6.
[10] Kao AH, Manzi S. How to manage patients with cardiopulmonary
disease? Best Pract Res Clin Rheumatol 2002;16:211–27.
[11] Ring-Mrozik E, Hecker WC, Nerlich A. Lobar emphysema and
atelectasis syndrome: a nosological unity. Eur J Pediatr Surg 1995;5:
131–5.
[12] Olmedo G, Poleri C, Rojas O, et al. Rounded atelectasis: another
pulmonary pseudotumor. Medicina (B Aires) 1994;54:641–5.
[13] Mulvey DA, Elliott MW, Koulouris NG, et al. Sniff esophageal and
nasopharyngeal pressures and maximal relaxation rates in patients with
respiratory dysfunction. Am Rev Respir Dis 1991;143:950–3.
[14] Mittoo S, Fell CD. Pulmonary manifestations of systemic lupus
erythematosus. Semin Respir Crit Care Med 2014;35:249–54.
[15] Eberlein M. Shrinking lung syndrome as a manifestation of pleuritis: are
surface forces and surfactant the pathophysiological link? J Rheumatol
2013;40:1926.
[16] Henderson LA, Loring SH, Gill RR, et al. Shrinking lung syndrome as a
manifestation of pleuritis: a new model based on pulmonary physiologi-
cal studies. J Rheumatol 2013;40:273–81.
[17] Carmier D, Diot E, Diot P. Shrinking lung syndrome: recognition,
pathophysiology and therapeutic strategy. Expert Rev Respir Med
2011;5:33–9.
[18] Carmier D, Marchand-Adam S, Diot P, et al. Respiratory involvement in
systemic lupus erythematosus. Rev Mal Respir 2010;27:66–78.
[19] Ernest D, Leung A. Ventilatory failure in shrinking lung syndrome is
associated with reduced chest compliance. Intern Med J 2010;40:66–8.
[20] Souza Neves F, da Silva TH, Paviani G, et al. Reinforcing a medical
hypothesis with a new question: is there a subgroup of shrinking lungs
syndrome that is induced by pleurisy in systemic lupus erythematosus
and is this subgroup marked by anti-Ro/SSA? Clin Rheumatol 2010;
29:777–9.
[21] Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifes-
tations of systemic lupus erythematosus: old and new concepts. Best Pract
Res Clin Rheumatol 2009;23:469–80.
[22] Butterly SJ, Pillans P, Horn B, et al. Off-label use of rituximab in a tertiary
Queensland hospital. Intern Med J 2010;40:443–5.
[23] Carmier D, Marchand-Adam S, Diot P, et al. Respiratory involvement in
systemic lupus erythematosus. Rev Mal Respir 2008;25:1289–303.
[24] Bertoli AM, Vila LM, Apte M, et al. LUMINA Study GroupSystemic
lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII:
factors predictive of pulmonary damage. Lupus 2007;16:410–7.
[25] Traynor AE, Corbridge TC, Eagan AE, et al. Prevalence and reversibility
of pulmonary dysfunction in refractory systemic lupus: improvement
correlates with disease remission following hematopoietic stem cell
transplantation. Chest 2005;127:1680–9.
[26] Martusewicz-Boros M, Wiatr E, Płodziszewska M, et al. Lung [54] Benham H, Garske L, Veccio P, et al. Successful treatment of shrinking
Borrell et al. Medicine (2016) 95:33 Medicineinvolvement in systemic lupus erythematosus (SLE): own experience.
Pneumonol Alergol Pol 2002;70:12–24.
[27] Warrington KJ,Moder KG, BrutinelWM. The shrinking lungs syndrome
in systemic lupus erythematosus. Mayo Clin Proc 2000;75:467–72.
[28] Olivé A. Shrinking or collapsed lung: that is the question. Med Clin
(Barc) 1996;107:39.
[29] Burns NS, Stevens AM, Iyer RS. Shrinking lung syndrome complicating
pediatric systemic lupus erythematosus. Pediatr Radiol 2014;44:
1318–22.
[30] Meinicke H, Heinzmann A, Geiger J, et al. Symptoms of shrinking lung
syndrome reveal systemic lupus erythematosus in a 12-year-old girl.
Pediatr Pulmonol 2013;48:1246–9.
[31] Krych EH, Fischer PR, Wylam ME. Pleural fibrosis mediates shrinking
lungs syndrome in children. Pediatr Pulmonol 2009;44:90–2.
[32] Ferguson PJ, Weinberger M. Shrinking lung syndrome in a 14-year-old
boy with systemic lupus erythematosus. Pediatr Pulmonol 2006;41:
194–7.
[33] Nadorra RL, Landing BH. Pulmonary lesions in childhood onset
systemic lupus erythematosus: analysis of 26 cases, and summary of
literature. Pediatr Pathol 1987;7:1–8.
[34] Thompson PJ, Dhillon DP, Ledingham J, et al. Shrinking lung,
diaphragmatic dysfunction and systemic lupus erytematosus. Am Rev
Respir Dis 1985;132:926–8.
[35] Meena M, DeStephano CC, Watson WJ, et al. Shrinking lung syndrome
in pregnancy complicated by antiphospholipid antibody syndrome.
Obstet Gynecol 2011;117:506–8.
[36] Singh R, HuangW,Menon Y, et al. Shrinking lung syndrome in systemic
lupus erythematosus and Sjogren’s syndrome. J Clin Rheumatol 2002;
8:340–5.
[37] Guleria VS, Singh PK, Saxena P, et al. Shrinking lung syndrome in
systemic lupus erythematosus-scleroderma overlap. Lung India
2014;31:407–9.
[38] Allen D, Fischer A, Bshouty Z, et al. Evaluating systemic lupus
erythematosus patients for lung involvement. Lupus 2012;21:1316–25.
[39] Gibson CJ, Edmonds JP, Hughes GR. Diaphragm function and lung
involvement in systemic lupus erythematosus. Am J Med 1977;63:
926–32.
[40] Gheita TA, Azkalany GS, El-Fishawy HS, et al. Shrinking lung syndrome
in systemic lupus erythematosus patients; clinical characteristics, disease
activity and damage. Int J Rheum Dis 2011;14:361–8.
[41] Elkayam O, Segal R, Caspi D, et al. Restrictive lung disease due to
diaphragmatic dysfunction in systemic lupus erythematosus. Two case
reports. Clin Exp Rheumatol 1992;10:267–9.
[42] Rubin LA, Urowitz MB. Shrinking lung syndrome in SLE: a clinical
pathologic study. J Rheumatol 1983;10:973–6.
[43] Hoffbrand BI, Beck ER. Unexplained dyspnoea and shrinking lung in
systemic lupus erytematosus. Br Med J 1965;1:1273–7.
[44] Martens J, Demedts M, Vanmeenen MT, et al. Respiratory muscle
dysfunction in systemic lupus erytematosus. Chest 1983;84:170–5.
[45] Wilcox PG, Stein HB, Clarke SD, et al. Phrenic nerve function in patients
with diaphragmatic weakness and systemic lupus erytematosus. Chest
1988;93:352–8.
[46] Pines A, Kaplinsky N, Olchovsky D, et al. Pleuro-pulmonary
manifestations of systemic lupus erythematosus: clinical features of its
subgroups: prognostic and therapeutic implications. Chest 1985;88:
129–35.
[47] Muñoz-Rodríguez FJ, Font J, Badia JR, et al. Shrinking lungs syndrome
in systemic lupus erythematosus: improvement with inhaled beta-agonist
therapy. Lupus 1997;6:412–4.
[48] Toya SP, Tzelepis GE. Association of the shrinking lung syndrome in
systemic lupus erythematosus with pleurisy: a systematic review. Semin
Arthritis Rheum 2009;39:30–7.
[49] De Santis M, Martins V, Moita J. Shrinking lung syndrome: case report
and literature review. Rev Port Pneumol 2010;16:687–91.
[50] Calderaro DC, Ferreira GA. Presentation and prognosis of shrinking
lung syndrome in systemic lupus erythematosus: report of four cases.
Rheumatol Int 2012;32:1391–6.
[51] Hemmati I, Blocka K. Shrinking lung syndrome masked by pleuro-
pericarditis: a case report and review of the literature. Clin Rheumatol
2012;31:1740–4.
[52] Peñacoba Toribio P, Córica Albani ME, Mayos Perez M, et al.
Rituximab en el tratamiento del síndrome del pulmón encogido del lupus
eritematoso sistémico. Reumatol Clin 2014;10:325–7.
[53] Pérez de Llano LA, Castro-Añon O, López MJ, et al. Shrinking lung
síndrome caused by lupus myopathy. Q J Med 2011;104:259–62.8
lung síndrome with rituximab in a patient with systemic lupus
erytematosus. J Clin Rheumatol 2010;16:68–70.
[55] Vilaplana-García R, Trujillo-Santos AJ, Vera-Méndez FJ. Síndrome del
“pulmón pequeño”, una rara manifestación del lupus eritematoso
sistémico. Arch Bronconeumol 2008;44:341–2.
[56] Oud KT, Bresser P, ten Berge RJ, et al. The shrinking lung syndrome in
systemic lupus erytematosus: improvement with corticosteroid therapy.
Lupus 2005;14:959–63.
[57] Al-Raqum HA, Uppal SS, Al-Mutairy M, et al. Shrinking lung síndrome
as a presenting manifestation of systemic lupus erytematosus in a female
Kuwaiti. Clin Rheumatol 2006;25:412–4.
[58] KarimMY,Miranda LC, Tench CM, et al. Presentation and prognosis of
the shrinking lung syndrome in systemic lupus erythematosus. Semin
Arthritis Rheum 2002;31:289–98.
[59] Langenskiöld E, Bonetti A, Fitting JW, et al. Shrinking lung syndrome
successfully treated with rituximab and cyclophosphamide. Respiration
2012;84:144–9.
[60] Costa CA, Castro JRDO, Jezler S, et al. Shrinking lung syndrome in
systemic lupus erythematosus. J Bras Pneumol [online] 2004;30:261–3.
[61] Van Veen S, Peeters AJ, Sterk PJ, et al. The “Shrinking lung syndrome” in
SLE, treatment with theophylline. Clin Reumatol 1993;12:462–5.
[62] Smiti Khanfir M, Bel Feki N, Said F, et al. Shrinking lung syndrome in
systemic lupus erythematosus. Am J Med Case Rep 2015;3:66–8.
[63] Walz-Leblanc BAE, Urowitz MB, Gladman D, et al. Shrinking lung
syndrome in systemic lupus erythematosus: improvement with cortico-
steroid therapy. J Rheumatol 1992;19:1970–2.
[64] Al-Kheir A, Al-Mobeireek A, Altahan A, et al. Shrinking lung syndrome
in systemic lupus erytematosus. Bahrain Med Bull 2003;25:50–1.
[65] Jacobelli S, Moreno R,Massardo L, et al. Inspiratory muscle dysfunction
and unexplained dyspnea in systemic lupus erythematosus. Arthritis
Rheum 1985;28:781–8.
[66] Hardy K, Herry I, Attali V, et al. Bilateral phrenic paralysis in a patient
with systemic lupus erythematosus. Chest 2001;119:1274–7.
[67] Hawkins P, Davison AG, Dasgupta B, et al. Diaphragm strength in acute
systemic lupus erythematosus in a patient with paradoxical abdominal
motion and reduced lung volumes. Thorax 2001;56:329–30.
[68] Cavallasca JA, Dubinsky D, Nasswette GG. Shrinking lungs syndrome: a
rare manifestation of systemic lupus erythematosus. Int J Clin Pract
2006;60:1683–6.
[69] Pillai S,Mehta J, Levin T, et al. Shrinking lung syndrome presenting as an
initial pulmonary manifestation of SLE. Lupus 2014;23:1201–3.
[70] Jeanmenne T, Singh NK, Pick M. Shrinking lung syndrome. BMJ Case
Rep 2009;2009:pii.bcr.08.2008.0825.
[71] Laroche CM,Mulvey DA, Hawkins PN, et al. Diaphragm strength in the
shrinking lung syndrome of systemic lupus erytematosus. Q J Med
1989;71:429–39.
[72] Soubrier M, Dubost JJ, Piette JC, et al. Shrinking lung syndrome in
systemic lupus erythematosus: a report of three cases. Rev Rhum Engl Ed
1995;62:395–8.
[73] De Filippis LG, Caliri A, Bagnato G. Shrinking lung syndrome in a
patient with recent systemic lupus erythematosus onset: a case report.
Panminerva Med 2008;50:193–4.
[74] Nemec M, Pradella M, Jahn K, et al. Magnetic resonance imaging–-
confirmed pleuritis in systemic lupus erythematosus-associated shrinking
lung syndrome. Arthritis Rheumatol 2015;67:1880.
[75] Munoz ML, Gelber AC, Houston BA. Into thin air: shrinking lung
syndrome. Am J Med 2014;127:711–3.
[76] Branger S, Schleinitz N, Gayet S, et al. Shrinking lung syndrome and
systemic auto-immune disease. Rev Med Interne 2004;25:83–90.
[77] Stevens WM, Burdon JG, Clemens LE, et al. The ’shrinking lungs
syndrome’: an infrequently recognised feature of systemic lupus
erythematosus. Aust N Z J Med 1990;20:67–70.
[78] Ugarte A, Ruiz-Irastorza G. SLE: the changing prognosis. Lupus 2016;
Jun 15 [Epub ahead of print].
[79] Kasturi S, Sammaritano LR. Corticosteroids in lupus. Rheum Dis Clin
North Am 2016;42:47–62.
[80] Sant’ Ambrogio G, Sant’Ambrogio FB. Crystal RG, West JB, Weibel ER,
et al. Reflexes from the upper airway, lungs, chest wall, and limbs. The
Lung: Scientific Foundations. Philadelphia:Lippincott-Raven; 1997.
1805–19.
[81] Butler JE, McKenzie DK, Gandevia SC. Reflex inhibition of human
inspiratory muscles in response to contralateral phrenic nerve stimula-
tion. Respir Physiol Neurobiol 2003;138:87–96.
[82] Bellingham MC. Synaptic inhibition of cat phrenic motor neurons by
internal intercostal nerve stimulation. J Neurophysiol 1999;82:1224–32.
[83] Homma I. Inspiratory inhibitory reflex caused by the chest wall vibration [89] Nishino T, Shimoyama N, Ide T, et al. Experimental pain augments
Borrell et al. Medicine (2016) 95:33 www.md-journal.comin man. Respir Physiol 1980;39:345–53.
[84] Knill R, Bryan AC. An intercostal-phrenic inhibitory reflex in human
newborn infants. J Apply Physiol 1976;40:352–6.
[85] Remmers JE. Inhibition of inspiratory activity by intercostal muscle
afferents. Respir Physiol 1970;10:358–83.
[86] Jammes Y, Delpierre S. Respiratory and circulatory effects of parietal
pleural afferent stimulation in rabbits. J Appl Physiol 2006;100:
1539–46.
[87] Ayoub J, Cohendy R, Prioux J, et al. Diaphragm movement before and
after cholecystectomy: a sonographic study. Anesth Analg 2001;92:
755–61.
[88] Desai PM. Pain management and pulmonary dysfunction. Crit Care Clin
1999;15:151–66.9
experimental dyspnea, but not vice versa in human volunteers.
Anesthesiology 1999;91:1633–8.
[90] Gibson GJ, Pride NB, Davis JN, et al. Pulmonary mechanics in patients
with respiratory muscle weakness. Am Rev Respir Dis 1997;115:
389–95.
[91] De Troyer A, Borenstein S, Cordier R. Analysis of lung volume restriction
in patients with respiratory muscle weakness. Thorax 1980;35:603–10.
[92] Estenne M, Gevenois PA, Kinnear W, et al. Lung volume restriction in
patients with chronic respiratory muscle weakness: the role of micro-
atelectasis. Thorax 1993;48:698–701.
[93] Eberlein M. Shrinking lung syndrome as a manifestation of pleuritis: are
surface forces and surfactant the pathophysiological link? J Rheumatol
2013;40:1926.
